The signing of the National Cancer Act in 1971 was designed to take laboratory discoveries rapidly from the bench to the bedside. A "war on cancer" had been declared. Combination cytotoxic chemotherapy was predicted to cure all cancers, based on the stunning success in treating childhood leukemia. Breast cancer treatments were primitive; radical mastectomy and radiation were standard of care for disease that had not spread. Ablative endocrine surgery (oophorectomy, hypophysectomy, and adrenalectomy) was a palliative last option for metastatic breast cancer. However, only 30% responded, surviving for only 1 or 2 years: every patient soon died. The discovery of the estrogen receptor (ER) and translation to breast cancer treatment triggered a revolution in women's health. Two important but interconnected events occurred in 1972 at the Worcester Foundation for Experimental Biology (WFEB) that would exploit the breast tumor ER as the first target to save lives and prevent breast cancer development. Two new groups of medicinesselective ER modulators (SERMs) and aromatase inhibitors (AIs)-would continue the momentum of research at the WFEB to improve women's health. Here, we recount the important progress made in women's health based on knowledge of the endocrinology of breast cancer. We propose future opportunities in SERM therapeutics to "refresh" the current standards of care for breast cancer treatment. The opportunity is based on emerging knowledge about acquired resistance to long-term adjuvant AI therapy used to treat breast cancer. (Endocrinology 159: 2980(Endocrinology 159: -2990(Endocrinology 159: , 2018 
A current search of the Web of Science (http:/apps. webofknowledge.com) illustrates use of specific words, the extent of past publications in breast cancer (488,227), aromatase inhibitors (AIs; 9897), estrogen receptor (ER; 94,000), tamoxifen (29, 610) , selective ER modulators (SERMs; 3930), raloxifene (4251), antiestrogens (2800), or estrogens (176,371). By contrast, until 1971, with the signing of the National Cancer Act, numbers were low or nonexistent: breast cancer (2111), AIs (0), ER (53) , tamoxifen (0), SERMs (0), raloxifene (0), and antiestrogens (58; counted from V.C.J.'s PhD thesis as all inclusive). In 1971, there was no agreed reference word for today's "antiestrogen" or "SERMs"; the words used to describe antiestrogenic compounds were antifertility agent, estrogen antagonist, and estrogen analogs. Estrogen records 5342 in the Web of Science in 1971. Today's change illustrates the earlier focus on elucidating sex steroid action in general physiology and the control of reproduction. Research into the treatment of cancer was considered hopeless by industry and academia, and breast cancer treatment was a basic end-oflife palliation.
In the first 70 years of the 20th century, treatment of primary breast cancer relied on radical mastectomy and radiotherapy (1) . Metastatic breast cancer (MBC) was treated by oophorectomy, hypophysectomy, or adrenalectomy, depending on menopausal status (2) . Estrogen was recognized as the hormone that stimulated breast cancer growth (2) . Paradoxically, high-dose synthetic estrogen treatment became the endocrine treatment of choice for postmenopausal patients with MBC, but treatment was effective only if used for 5 years after menopause (3, 4) . Predictive tests to determine which patients with MBC would respond to either high-dose estrogen or endocrine-ablative surgery were not available. Mechanisms of estrogen action were unknown.
The extensive complimentary studies of Jensen et al. (5) and Gorski et al. (6) provided a target that translated from estrogen target tissues in laboratory animals (uterus, vagina, pituitary gland) to breast cancer (7) to predict the response of MBC to endocrine therapy. The clinical ER assay for breast cancer biopsies of MBC was introduced into patient care in 1975, after the 1974 Consensus Conference in Bethesda, Maryland (8) . The rationale for the clinical ER assay was to avoid hospitalization and endocrine-ablative surgery for those MBC patients whose tumor was ER negative, i.e., hormone independent, and as a result should not be treated with endocrine ablation. This accounted for ;20% of MBC patients. By contrast, the MBC patient who had an ER-positive tumor had a 60% response rate to either high-dose synthetic estrogen or endocrineablation therapy (9) .
Knowledge of the tumor ER target initially stimulated little interest in the development of targeted therapies to emasculate the estrogen: ER complex in breast cancer. Antiestrogenic compounds were available in the 1960s (10) , but the primary interest by the pharmaceutical industry was focused on "morning-after" contraceptives or treatments for gynecologic conditions in the wake of the clinical success of the oral contraceptive (11, 12) . In the cancer research community, few cared about endocrine approaches to cancer therapy. In a major review of the basic and clinical uses of antiestrogens in 1975 (12) , the authors devote only 14 lines and three references to applications in breast cancer. Their article totaled 15 pages and 180 references. Reproductive endocrinology was the focus of their clinical applications. The review closes, "Relatively little has been done to apply the results of animal experiments to humans, but there is now enough evidence to suggest that antiestrogens have a great potential application to human therapy. A promising approach is to tailor make particular antiestrogen for specific indications-for example ovulation induction or antifertility or anticancer" (12) .
At the beginning of the 1970s, combination cytotoxic chemotherapy was king for the treatment of all cancers. This was because combination cytotoxic chemotherapy had accomplished an enormous advance in the survival of children with leukemia (13) . Nevertheless, the signing of the National Cancer Act in 1971 by President Nixon created a new mechanism to take promising medicines and treatment strategies from the bench to the bedside. The science of endocrinology was to play a central role in the way forward, which would ultimately lead to the development of ICI 46,474 (tamoxifen), the pioneering SERM, and 4-hydroxyandrostenedione (formestane), the pioneering specific AI (14) .
This mini-review will recount the start of targeted cancer therapy with precision medicines at the Worcester Foundation for Experimental Biology (WFEB) in Shrewsbury, Massachusetts. We will document the twists and turns of research that resulted in a sustained improvement in women's health. The change that occurred over the last 40 years, catalyzed by translational research, resulted in the development of two new groups of medicines, SERMs and AIs, for the treatment and prevention of breast cancer. Additionally, the SERMs would be used to treat, and have the potential to prevent, major diseases (osteoporosis, breast cancer, coronary heart disease, strokes) in postmenopausal women.
Two Strategies for Targeted Therapy
The WFEB is the "home of the oral contraceptive." This independent research institute was the world center for steroid endocrinology with a world-class steroid training program for postdoctoral fellows. Drs. Gregory Pincus and Hudson Hoagland were cofounders of the WFEB in 1944. They recruited a Chinese scientist, Dr. M. C. Chang, to confirm in the laboratory the contraceptive properties of new synthetic progestogens. Through subsequent successful clinical trials, conducted by Dr. John Rock, the oral contraceptive entered clinical practice in the 1960s.
With the passing of the National Cancer Act in 1971, the world of government-sponsored science moved from the regulation of reproduction to cancer research and treatment. Dr. Elwood Jensen, director of the Ben May Laboratories at the University of Chicago, was appointed to the Scientific Advisory Board of the WFEB in 1971. The strategic goal of his appointment was to facilitate a shift in the scientific focus of the foundation and harness the rich environment of endocrinology for cancer research and treatment. This he did at the Ben May Laboratories, with a training course in the latest methods to measure the ER in breast tumors (for V.C.J.), thus facilitating importation of the dimethylbenzanthrancene (DMBA)-induced rat mammary carcinoma model to the WFEB (V.C.J.). The DMBA-induced rat mammary carcinoma model was the only laboratory model available for hormone-responsive breast cancer research; the tumors were ER positive, and ovariectomy caused tumor regression (15, 16) . These techniques were essential to initiate laboratory studies with a failed "morning-after pill" ICI 46,474 (soon to become tamoxifen) and devise a way forward that could be tested in clinical trials (17, 18) . This was achieved during the 1970s with an evidence-based strategy consisting of three elements: (1) only selecting ER-positive breast cancer patients for tamoxifen treatment (19), (2) using long-term adjuvant tamoxifen therapy after breast cancer surgery (18) , and (3) the clinical potential of chemoprevention of breast cancer demonstrated in animals (20) . These early lines of research with tamoxifen to target the ER have been fully documented previously (21) , and only the current clinical results using tamoxifen therapy will be summarized later.
Our focus will be the advance with AIs that prevent estrogen synthesis in postmenopausal women by targeting cytochrome P 450 19 (CYP19). In the early 1970s, the Brodies (Angela and Harry) at the WFEB were advancing this alternative targeted approach for the treatment of breast cancer. Their philosophy was that "there is no antiestrogen better than no estrogen at all." This would result in their discovery of formestane to block irreversibly the aromatase enzyme CYP19. This pioneering research strategy harnessed the expertise in steroid biochemistry at the WFEB and will be described in detail.
Formestane, the First Specific AI
Previous studies with testolactone (22) and aminoglutethimide (23) demonstrated inhibition of the aromatase enzyme. Both agents had been studied for the treatment of breast cancer (24) (25) (26) (27) . Unfortunately, both agents are neither specific nor very potent. Furthermore, the requirement to supplement patients with glucocorticoids during therapy with aminoglutethimide increased side effects (27) . Swarzel et al. (28) , using the human placental microsome assay developed by Ryan (29) at Harvard, reported that a number of steroidal compounds that inhibited aromatase and formestane were subsequently found to be the most potent (30) (31) (32) . The major advantage of formestane, compared with aminoglutethimide, is that formestane irreversibly binds to the aromatase enzyme causing inactivation (33, 34) . This suicide inhibitor of aromatase CYP19 requires resynthesis of the enzyme if estrogen biosynthesis is to be revived. The studies in vitro were advanced to studies in vivo in female rats. Administration of formestane at proestrus dramatically decreased estrogen production (33) . Subsequent studies in rhesus monkeys demonstrated that formestane is rapidly cleared from the circulation (35) . Nevertheless, administration of formestane to rhesus monkeys had a sustained biological effect on the inhibition of aromatase activity. Peripheral aromatization did not return to control levels until 7 days after treatment stopped (36) .
Before clinical testing, antitumor studies with formestane were conducted using the DMBA-induced rat mammary carcinoma model. Harry Brodie was taught the model by V.C.J., and Angela was not allowed into the laboratory during DMBA tumor initiation. We were very cautious of Angela's safety. Administration of formestane, twice weekly for 4 weeks, caused DMBA tumor regression in the majority (90%), by .50%, and many small tumors disappeared completely (31) . Ovarian estrogen production was significantly reduced (33) , and coadministration of estradiol stopped tumor regression. Responsiveness to formestane was long lived during therapy for up to 5 months (37) .
A comparison of the antitumor effects of formestane with tamoxifen was instructive (38) . Tamoxifen was less effective than formestane at causing DMBAinduced tumor regression, and a combination of formestane and tamoxifen was inferior to formestane alone. This laboratory result, completed in the 1980s, was to be predictive of the Anastrozole, Tamoxifen, Alone or in Combination Trial, completed 15 years later (39) . The result of the clinical trial demonstrated that anastrozole alone was superior at controlling recurrences compared with either tamoxifen-treated patients or the combination. It is a rule of pharmacology that when a medicine (anastrozole) that prevents the synthesis of a full agonist (estradiol) for a receptor (ER) is administered with a partial agonist (tamoxifen), the biological effect of the combination (anastrozole + tamoxifen) will be equivalent to the partial agonist (tamoxifen) alone.
Clinical Testing of Formestane
The acute LD 50 for formestane is 4.325 g/kg in mice, thereby establishing low toxicity. The first trial (40) of 11 patients, aged between 36 and 75 years, was all postmenopausal, either naturally or oophorectomized. The trial was unique by today's standards, as the work was not supported by any pharmaceutical company. The formestane was synthesized at the University of Maryland, as previously reported (31), formulated, and administered (500 mg) to patients IM, once per week as a suspension of 0.5% carboxymethylcellulose in water. All patients had previously responded to endocrine therapy and relapsed. Only four patients had ER determinations. There were four partial responses and one stable disease lasting .12 weeks (40). This preliminary study attracted much attention, and a later study, with formestane supplied by Ciba-Geigy Pharmaceuticals under the code name CGP 32346, was a phase II study of 52 assessable postmenopausal patients with MBC. There were 14 who responded (27%), 10 had stable diseases (19%), and the rest progressed. A surprising finding was that formestane failed to suppress total estrogen levels, but patients whose estradiol levels were suppressed by .50% responded (41) . The reason for this finding remains obscure, but these data demonstrate that reduction of circulating estradiol is the key factor in the antitumor actions of formestane.
Unfortunately, the limitation of formestane use was the fact that it was an injectable. Oral administration was assessed successfully (42) using a single IM injection of 125 mg formestane and compared with daily oral administration of 500 mg formestane for seven consecutive days. Similar decreases in estradiol occurred by both routes of administrations, but an increase in estradiol occurred more rapidly after oral dosing stopped.
The encouraging clinical data with formestane triggered a search by the pharmaceutical industry for new orally active AIs. This was at exactly the time that tamoxifen was showing promise as a long-term (5-year) adjuvant therapy (43) that saved lives. There was a market now. The market for AIs expanded with the finding that tamoxifen increased human endometrial cancer growth in the laboratory (44) . A small but significant increase in the incidence of endometrial cancer in postmenopausal patients was noted (45) . No estrogen was likely to be better than tamoxifen for the treatment and prevention of breast cancer.
Discovery of Safe, Orally Active AIs
The pharmaceutical industry conducted focused laboratory screening of potential AIs for 20 years (1980 to 2000), and clinical trials of promising candidates were conducted in MBC on five candidates. Fadrozole and vorozole, the second-generation AIs, were tested rigorously in clinical studies but were discarded because of a lack of specificity for CYP19, resulting in endocrine sideeffects. Third-generation, orally active AIs (anastrozole, letrozole, exemestane) are all available for the treatment of MBC and as adjuvant therapies. Nevertheless, the clinical applications of the AIs were predetermined by the strategic success of tamoxifen, either as a long-term adjuvant treatment of breast cancer or with the application of tamoxifen to reduce the risk of breast cancer in high-risk populations of women. It should be noted, however, that tamoxifen continues to be used ubiquitously in both the pre-and postmenopausal setting, whereas the AIs are only used in postmenopausal patients unless an luteinizing hormone-releasing hormone superagonist is used in the premenopausal setting. As both tamoxifen and AIs followed a similar path of development as adjuvant therapies, they will be considered together.
Long-Term Adjuvant Tamoxifen or AI Therapy
The translational research strategy proposed in the late 1970s (17, 18, 46) ; i.e., target patients with ER-positive breast cancer and administered long-term (5 years or longer) adjuvant antihormone therapy became the clinical standards of care (47) . Five years of adjuvant tamoxifen monotherapy has been evaluated extensively by the Early Breast Cancer Trialist Collaborative Group (48) . Profound decreases in recurrence rates and decreases in mortality are noted. Surprisingly, tamoxifen treatment continues to benefit patients after adjuvant therapy stops. This is an important clinical observation. Tamoxifen is not a cytotoxic agent, but this "carryover effect" has been attributed (49) to the evolution of micrometastases to new forms of acquired tamoxifen resistance over a 5-year period.
Laboratory studies document that ER-positive breast cancer cells, inoculated into athymic mice, can display an initial, unique form of resistance to the SERM tamoxifen, i.e., tamoxifen-stimulated growth (50, 51) . Indeed, the breast tumors with early (1 to 2 years) acquired resistance can grow with either tamoxifen or estrogen. Additionally, the first novel selective ER degrader (SERD) (52) was tested in the model of acquired resistance to tamoxifen. The positive results led to the current clinical strategies of using either an AI or a SERD after the failure of tamoxifen treatment (53, 54) . Surprisingly, laboratory studies demonstrate that the continuation to retransplant breast tumors with early (1 to 2 years) acquired resistance to tamoxifen into tamoxifen-treated athymic mice for up to 5 years maintains tamoxifen-stimulated growth, but low-dose estrogen administration causes rapid tumor regression (55) . Here was an echo of Haddow's (3) rule regarding the value of estrogen therapy "five years after menopause" to treat MBC and the early standard of 5 years of adjuvant tamoxifen treatment (43, 48). The new biology of low-dose estrogen-stimulated tumor regression has been demonstrated clinically with estrogen therapy following recurrence during adjuvant AI therapy (56) .
Five years of adjuvant tamoxifen therapy was initially chosen as a safe optimal duration of treatment based on clinical trial data (57) . Nevertheless, recent studies by the Early Breast Cancer Trialist Collaborative Group (58) illustrate that the high-risk patient (large primary tumors and/or multiple axillary lymph node involvement) should be considered for extended adjuvant therapy with tamoxifen or an AI. Ten years of adjuvant tamoxifen treatment has now proven to be superior to 5 years of tamoxifen treatment (59). However, mortality decreases occur only at between 5 and 10 years of adjuvant tamoxifen in the 5 years after 10 years of adjuvant tamoxifen is completed. This again is the carryover effect. Goss et al. (60, 61) have driven the advance of using 5 and 10 years of AI therapy following an initial 5 years of adjuvant tamoxifen treatment. Indeed, decades ago, Goss was a member the clinical group that first evaluated the targeted AI formestane (40, 41) .
However, the destruction rather than the holding of the growth of micrometastases over time might now be a wise strategy. There are adjuvant trials of combinations of AIs with cyclin D kinase 4/6 inhibitors or mTOR inhibitors based on positive clinical responses for combination therapy of MBC (62) . However, high cost and decreases in adherence to long-term combination adjuvant AI therapy will conspire to reduce adherence (63) .
By contrast, the Study of Letrozole Extension Trial addresses drug holidays during long-term adjuvant AI therapy. Continuous letrozole for 5 years (after either 5 years of letrozole or tamoxifen) was compared with 5 years of letrozole, with the first 4 years having 3-month annual drug holidays and then continuous letrozole in year 5. It was reasoned that a woman's own estrogen would destroy the micrometastatic disease with acquired resistance (55) . The first planned analysis showed no difference between continuous or intermittent A1 therapy (64) . Nevertheless, two important conclusions can be drawn: (1) if there continues to be no negative difference in recurrence rates or mortality between continuous and intermittent AI, then this demonstrates that poor compliance by patients can be rescued (65) , and (2) the AI drug holiday can be used for combination therapeutics with precision medicines possibly using low-dose estrogen to enhance estrogen-induced apoptosis (66) . However, there is a concern for patient safety, but already, medicinal chemists have solved the problem with new compounds called selective human ER partial agonists (67) , which are raloxifene analogs that trigger apoptosis in breast cancer cells with long-term estrogen-deprived (LTED) acquired tamoxifen resistance without collateral estrogen action. These new medicines may eventually find a role in triggering apoptosis without the concern of estrogen use in breast cancer patients (68) . However, compliance is the key to all therapeutic interventions (63) .
By 2050, the incidence of breast cancer in the United States is estimated to rise by 50% from the incidence in 2011 (69); therefore, enhanced strategies to treat or prevent breast cancer need to be developed. The majority of these cancers will be ER positive, so issues of general health care must take precedence over "no estrogen alone" as the cornerstone principle of adjuvant therapy. The obvious solution would be to prevent breast cancer using either tamoxifen or an AI. However, the transition of tamoxifen, the front-runner, from cancer treatment to use in women without disease was complex. Based on the imperfect toxicology of tamoxifen, another solution emerged.
The Evolution of Tamoxifen Into the SERM Solution
The fact that tamoxifen (1) increases the risk of endometrial cancer in postmenopausal patients (45) and (2) is a hepatocarcinogen in Sprague-Dawley rats (70) (71) (72) restricted use of the medicine and naturally caused concern in women at high risk for endometrial or liver cancer. Initially, however, the fact that tamoxifen, a known antiestrogen, was to be used to prevent breast cancer in women without the disease raised concerns about the long-term effect of tamoxifen on bone physiology, osteoporosis, and coronary heart disease. These diseases are far more prevalent than breast cancer. At the time, it was believed that estrogen was essential to protect women from osteoporosis and coronary heart disease. The incidence of both diseases increases after menopause, so it was reasoned that the administration of an antiestrogen could only exacerbate the situation. It was known from early laboratory studies that tamoxifen lowered low-density lipoprotein cholesterol (this fact was noted in the company patent for tamoxifen) (73) , but the effect of antiestrogens on animal or human bone density was unknown. It was anticipated that an "antiestrogen" would be an antiestrogen in all estrogen target tissues, but this was not found to be the case. Tamoxifen and keoxifene (now known as raloxifene), an antiestrogen with none of the uterotrophic effects of tamoxifen, were as effective as estrogen in maintaining ovariectomized rat bone density (74) . These animal data were confirmed by others (75) . Additionally, tamoxifen and keoxifene were able to prevent rat mammary carcinogenesis (76) .
The evidence from the laboratory was followed by the clinical findings that tamoxifen reduced bone loss in postmenopausal women (77) and lowered low-density lipoprotein cholesterol (78) . A SERM could switch on or switch off estrogen target tissues around a woman's body. This was a unique pharmacology.
The SERM solution was simply stated (79): "Is this the end of the possible applications for antiestrogens? Certainly not. We have obtained valuable clinical information about this group of drugs that can be applied in other disease states. Research does not travel in straight lines and observations in one field of science often become discoveries in another. Important clues have been garnered about the effects of tamoxifen on bone and lipids so it is possible that derivatives could find targeted applications to retard osteoporosis or atherosclerosis. The ubiquitous application of novel compounds to prevent diseases associated with the progressive changes after the menopause may, as a side effect, significantly retard the development of breast cancer. The targeted population would be postmenopausal women in general, thereby avoiding the requirement to select a high risk population to prevent breast cancer."
The clinical strategies to prevent breast cancer in highrisk women or aim at treating osteoporosis and prevent breast cancer at the same time moved forward together. Tamoxifen reduced the incidence of breast cancer in preand postmenopausal women and the carryover effect was noted (80) by reducing breast cancer incidence even after tamoxifen was stopped. Raloxifene was tested successfully for the prevention of osteoporosis in highrisk postmenopausal women, with the anticipated simultaneous decrease in breast cancer (81) .
The Study of Tamoxifen and Raloxifene pitted tamoxifen against raloxifene to determine which medicine would be superior at reducing the incidence of postmenopausal breast cancer. Both SERMs were equally effective and reduced breast cancer incidence by 50% (82), but raloxifene had a better safety profile with regard to thromboembolic events and endometrial cancer. Interestingly, tamoxifen was superior once therapy was stopped, as raloxifene does not appear to have an equivalent carryover effect (82) . This was predicted by earlier animal studies (76) . An updated meta-analysis of SERMs to prevent breast cancer is available (83) .
AIs as Breast Cancer Chemopreventives
Two AIs, anastrozole (84) and exemestane (85) , have been successfully tested to reduce breast cancer incidence in high-risk populations of postmenopausal women. Results are excellent and better than would be predicted if a SERM was used as a comparator. Unlike SERMs, no AIs are Food and Drug Administration (FDA) approved to reduce breast cancer risk. Nevertheless, in the United Kingdom anastrozole is available through the National Health Service and is recommended for use by the National Institute for Health and Care Excellence, as are tamoxifen and raloxifene.
Summary of the SERM Solution
There are now five FDA-approved SERMs, each to treat or prevent diseases in postmenopausal women. Each of the molecules (tamoxifen, raloxifene, basedoxifene, ospemiphene, and toremifene) has origins in earlier basic research discoveries (86) (87) (88) during the rigorous study of the structure-function relationships of SERMs and pure antiestrogens (89, 90).
Raloxifene and basedoxifene were both designed to have high binding affinity for the ER. This property was dependent on the discovery that tamoxifen is metabolically activated to 4-hydroxytamoxifen (88, 91) . The parahydroxylation of tamoxifen is located in a position that is equivalent to the three-phenolic binding of estradiol within the ER. Likewise, the ligand-binding domain scaffold of basedoxifene is a potent estrogenic metabolite of the failed breast cancer drug zindoxifene (87) . Ospemifene is dependent on the discovery of metabolite Y of tamoxifen (86) . The antiestrogenic side chain of tamoxifen becomes a glycol formed by didemethylation followed by deamination. The equivalent metabolite of toremifene was subsequently discovered and developed as ospemifene for dyspareunia.
However, the potential of SERMs has become significantly improved with the clinical testing of lasofoxifene (92) . Not only is lasofoxifene active at one-100th of the dose used for raloxifene (60 mg daily) to reduce the risk of osteoporosis, but lasofoxifene also reduces strokes, vaginal atrophy, coronary heart disease, and breast cancer, with no increases in endometrial cancer.
The discovery and study of SERMs has opened up opportunities to develop medicines that address diseases never before anticipated. As a result, there is keen interest in modulating all members of the nuclear receptor superfamily (93) .
An Evidence-Based New SERM as a Precision Medicine
The advances in adjuvant therapy with AIs must now focus on the Achilles heel of cancer treatment: acquired drug resistance. Current technology with deep sequencing of primary breast tumors and recurrences has identified mutations in the recurrent tumor ER that are autostimulatory for growth. Some breast cancer cells that overproduce ER during LTED, now by trial and error, mutate ER to autostimulate growth in the absence of estrogen. Recurrences from adjuvant AI therapy have an incidence of mutations in the ER of ;25% (94) (95) (96) (97) . This is a target for therapeutics that is vulnerable to interruption early during adjuvant therapy.
All acquired resistance in cancer is a process of trial and error, resulting from indefinite, deregulated replication. It is the survival of the fittest. Laboratory studies with LTED for MCF7 (luminal A p53 wild-type) or T47D (luminal B p53 mutant) cells demonstrate that there are at least two forms of regulation for the ER (98) . Breast cancer cells (MCF7) increase ER synthesis or amplify the ER gene in an attempt to scavenge any estrogen at all to replicate. There is a 10-fold increase in ER in the absence of estrogen for MCF7 cells (99, 100) . In the case of T47D cells under LTED, the ER is lost (101, 102) , and ER-negative growth results.
The putative mechanism of autostimulation in the majority of mutated ER recurrent breast cancers has been deciphered recently through computer simulations (103) . Mutations in amino acid 537 or 538 now allow helix12 of the ER to close the empty ligand-binding domain. The mutated amino acids bind to an anchor amino acid, asp351. Receptor activation results and mutant ERmediated growth occurs. However, these recent data solutions are dependent on an early expanding database of the molecular pharmacology of ER over the past 25 years. Several important milestones occurred: (1) the previous identification of asp351 as a key amino acid in the estrogen-like effects of tamoxifen vs raloxifene (104) (105) (106) , (2) the autostimulator actions of ER amino acids 537 and 538, when mutated (107) (108) (109) , and (3) the X-ray crystallographic resolution of the ER ligand-binding domain with estradiol, diethylstilbestrol, 4-hydroxytamoxifen, and raloxifene (110, 111) . The mutated ERs in helix12 require an intact and available asp351 to seal the unoccupied ER and initiate cell replication. Based on this historical molecular pharmacology and current understanding of mechanisms of AI resistance, the key to combating AI resistance is to create a SERD that destroys the ER early during therapy. This medicine would replace AIs currently used in adjuvant therapy.
A SERD binds to ER to cause autodestruction of ER pools. However, despite the therapeutic value of fulvestrant (500 mg) as a once-monthly depot IM injection to treat MBC, this method of administration is unacceptable over years of adjuvant therapy. Currently, there is increased interest by medicinal chemists to create an orally active SERD to replace fulvestrant (62) . An orally active SERD has completed the first phase I clinical study (112) . However, we suggest this goal to maintain "estrogen-free women" is flawed strategically (113) . If an orally active SERD is to progress to adjuvant therapy, then there must be very few side effects. Over the months, serious side effects conspire to undermine compliance. The stopping of antiestrogen treatment results in tumor recurrence and death.
With our aging population and the projected increasing incidence of ER-positive breast cancer (69), we suggest an alternative strategy of creating a super-SERD, i.e., a carrier molecule with the known health-care advantages of a SERM that integrates an acrylic acid side chain that is known to destroy the ER complex. The acrylic acid side chain is a recurring feature of the structure-function relationships of orally active SERDs (62) . Medicinal chemists have already demonstrated that they can fulfill the promise of the ideal SERM proposed more than 25 years ago (79) . The proof of this statement is that five SERMs are FDA approved for different indications in women's health (114) . However, the clinical properties of lasofoxifene as a SERM that can reduce osteoporotic fractures, reduce breast cancer, not increase endometrial cancer, and decrease chronic heart disease and strokes include a remarkable success story (92) . The SERM GW5638 (115) , first reported in 1994, has an acrylic acid side chain and destroys the ER in breast cancer (116, 117) . Nevertheless, SERM action is retained in bones (115) . This approach to enhance women's health, while having the potential to prevent a known mechanism of acquired drug resistance to AIs, will reduce recurrences compared with an AI used as an adjuvant therapy. Compliance will be enhanced because of multiple health advantages for postmenopausal women.
Conclusion
The WFEB was the catalyst to change women's health. First, this was achieved by major translational advances in reproduction with the discovery and development of the oral contraceptive and the scientific foundations of in vitro fertilization in animals by Chang (118) . Knowledge of the science of in vitro fertilization resulted in the birth of Louise Brown in Great Britain on 25 July 1977. Second, the signing of the National Cancer Act in 1971 resulted in the discovery of two new groups of medicines: the SERMs and enzyme-specific AIs (14) .
We propose to "refresh" the standard in healthcare that currently uses continuous AI therapy for a decade. We propose (1) a pre-emptive salvage strategy of precision medicines to kill developing AI-resistant micrometastases in high-risk patients (68) and (2) a super-SERD to be developed with known medicinal chemistry as a replacement for AIs as adjuvant therapy (113) . The super-SERD will destroy ER and avoid a known mechanism of AI resistance, i.e., 25% of recurrences from AIs have a mutation to the ER. The medicinal chemistry of SERMs will be incorporated into the super-SERD to improve women's health and avoid the side effects of estrogen-free women (62, 68, 113) .
The aforementioned strategies will allow new medicines to contain the increases in breast cancer deaths, cardiovascular deaths, and deaths resulting from osteoporosis that will increase over the next two generations. Until we can prevent breast cancer, the goal of therapeutics is to maintain patients recurrence-free with cheap and effective maintenance-treatment strategies. Our strategic goal is to allow women to live their natural life expectancy after a diagnosis of ER-positive breast cancer.
and AIs. The SERM history can be found in the references of this mini-review, but readers can find an encyclopedic history of aromatase and its inhibitors in the reviews by Santen et 
